Fidia S.p.A. (BIT:FDA)
0.0529
-0.0021 (-3.82%)
At close: Mar 6, 2026
Fidia Revenue
Fidia had revenue of 13.59M EUR in the half year ending June 30, 2025, with 51.15% growth. This brings the company's revenue in the last twelve months to 21.13M, down -28.94% year-over-year. In the year 2024, Fidia had annual revenue of 17.53M, down -38.98%.
Revenue (ttm)
21.13M
Revenue Growth
-28.94%
P/S Ratio
0.04
Revenue / Employee
150.93K
Employees
140
Market Cap
788.21K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
| Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
| Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
| Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
| Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| OSAI Automation System | 41.92M |
| Clabo | 58.10M |
| Marzocchi Pompe | 37.06M |
| Esautomotion | 28.29M |
| ErreDue | 17.78M |
| Valtecne | 34.06M |
| ILPRA | 80.39M |
| SIT S.p.A. | 314.71M |
Fidia News
- 7 hours ago - Controversial FDA Vaccines Chief Vinay Prasad To Leave Agency In April - Benzinga
- 9 hours ago - Lantheus : FDA Approves PYLARIFY TruVu, New PSMA Imaging Agent For Prostate Cancer - Nasdaq
- 9 hours ago - U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis - Benzinga
- 10 hours ago - Top FDA regulator to leave the agency - The Hill
- 12 hours ago - Incyte Corporation (INCY) Receives FDA Complete Response Letter for Zynyz® sBLA - GuruFocus
- 13 hours ago - Trump administration’s embattled FDA vaccine chief ousted for the second time - The Guardian
- 13 hours ago - Moderna Pops As Vinay Prasad, The FDA's Controversial Vaccine Head, Will Depart In April - Investor's Business Daily
- 13 hours ago - Controversial FDA vaccine chief Dr. Vinay Prasad exits agency again - Associated Press